SEARCH

SEARCH BY CITATION

References

  • Baron, F., Little, M.T. & Storb, R. (2005) Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. Blood Reviews, 19, 153164.
  • Dudley, M.E., Wunderlich, J.R., Yang, J.C., Sherry, R.M., Topalian, S.L., Restifo, N.P., Royal, R.E., Kammula, U., White, D.E., Mavroukakis, S.A., Rogers, L.J., Gracia, G.J., Jones, S.A., Mangiameli, D.P., Pelletier, M.M., Gea-Banacloche, J., Robinson, M.R., Berman, D.M., Filie, A.C., Abati, A. & Rosenberg, S.A. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. Journal of Clinical Oncology, 23, 23462357.
  • Eichhorst, B.F., Busch, R., Hopfinger, G., Pasold, R., Hensel, M., Steinbrecher, C., Siehl, S., Jaeger, U., Bergmann, M., Stilgenbauer, S., Schweighofer, C., Wendtner, C.M., Doehner, H., Brittinger, G., Emmerich, B. & Hallek, M. (2005) Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood, doi:10.1182/blood-2005-06-2395.
  • Griffith, L.M., McCoy, Jr, J.P., Bolan, C.D., Stroncek, D.F., Pickett, A.C., Linton, G.F., Lundqvist, A., Srinivasan, R., Leitman, S.F. & Childs, R.W. (2005) Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. British Journal of Haematology, 128, 668675.
  • O'Brien, S.M., Kantarjian, H.M., Cortes, J., Beran, M., Koller, C.A., Giles, F.J., Lerner, S. & Keating, M. (2001) Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Journal of Clinical Oncology, 19, 14141420.
  • Srinivasan, R., Balow, J.E., Sabnis, S., Lundqvist, A., Igarashi, T., Takahashi, Y., Austin, H., Tisdale, J., Barrett, J., Geller, N., Childs, R. (2005) Nephrotic syndrome: an under-recognised immune mediated complication of non-myeloablative hematopoietic stem cell transplantation. British Journal of Haematology, 131, 7479.